Abstract

Clostridium difficile is a Gram-positive spore-forming pathogen and a leading cause of nosocomial diarrhea. C. difficile infections are transmitted when ingested spores germinate in the gastrointestinal tract and transform into vegetative cells. Germination begins when the germinant receptor CspC detects bile salts in the gut. CspC is a subtilisin-like serine pseudoprotease that activates the related CspB serine protease through an unknown mechanism. Activated CspB cleaves the pro-SleC zymogen, which allows the activated SleC cortex hydrolase to degrade the protective cortex layer. While these regulators are essential for C. difficile spores to outgrow and form toxin-secreting vegetative cells, the mechanisms controlling their function have only been partially characterized. In this study, we identify the lipoprotein GerS as a novel regulator of C. difficile spore germination using targeted mutagenesis. A gerS mutant has a severe germination defect and fails to degrade cortex even though it processes SleC at wildtype levels. Using complementation analyses, we demonstrate that GerS secretion, but not lipidation, is necessary for GerS to activate SleC. Importantly, loss of GerS attenuates the virulence of C. difficile in a hamster model of infection. Since GerS appears to be conserved exclusively in related Peptostreptococcaeace family members, our results contribute to a growing body of work indicating that C. difficile has evolved distinct mechanisms for controlling the exit from dormancy relative to B. subtilis and other spore-forming organisms.

Highlights

  • Clostridium difficile is a Gram-positive spore-former capable of causing diarrheal disease that can lead to fatal colitis

  • We describe the identification of a novel regulator of C. difficile spore germination, CD3464 in strain 630, referred to as GerS, which is conserved among sequenced Peptostreptococcaceae family members

  • We previously conducted RNA-Seq analyses of C. difficile sporulation-specific sigma factor mutants to identify gene products that might be required for spore formation and/or germination [40,41]

Read more

Summary

Introduction

Clostridium difficile is a Gram-positive spore-former capable of causing diarrheal disease that can lead to fatal colitis. C. difficile infections have primarily been associated with individuals undergoing antibiotic therapy, but long hospitalizations, underlying comorbidities, community-acquired infections, and age-related risk factors have been documented [4,5,6]. These complications lead to C. difficile disease treatment costs between $1–5 billion per year in the United States [7,8]. Of the 0.5 million C. difficile infections in the United States each year, approximately 30,000 lead to death [9]. These deaths are primarily due to recurrent C. difficile infections, which occur in ~20–30% of people that clear the first infection [9,10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call